



In The Name Of GOD

Antibody screening and RBC phenotype

By:

Fatemeh.Mirzaeyan PhD of hematology and blood banking The head of immunohematology lab of Tehran blood center

AABB, Modern Blood Banking







Potentially clinically significant antibody

□ Associated with HDFN.

□ Associated with HTR.

□ Notably decreased survival of transfused red cells.

Reactive at either 37 C or in the AHG test phase are more likely to be clinically significant than cold-reactive antibodies.



Antibodies to red cell antigens



□ In chronically transfused patient ~14% to 50% are reported to be alloimmunized.

Antibodies detected in serologic tests may be passively acquired.
 -Injected immunoglobulin.
 -Donor plasma.
 -Passenger lymphocytes in transplanted organs.

-Hematopoietic progenitor cells (HPCs).

PREANALYTICAL CONSIDERATIONS

- Mycoplasma pneumoniae (anti-1)
- Infectious mononucleosis (anti-i).
- Patients with paroxysmal cold hemoglobinuria(anti-P).
- Warm autoantibodies (systemic lupus erythematosus, multiple myeloma, chronic lymphocytic leukemia, or lymphoma).
- solid-organ or HPC transplants (passive antibodies).
- Drugs
- (IVIG) and (RhIG) can interfere with antibody-screening tests.







Antibody Screening

Cell	D	С	С	Ε	е	Cw	K	k	Kp ^a	Кр ^ь	Js ^a	Js ^b	Fy ^a	Fy ^b	Jk ^a	Jk ^b	Le ^a	Le ^b	P ₁	М	N	S	s	Lu ^a	Lu ^b	Xg ^a		
R1R1	+	+	0	0	+	0	0	+	0	+	0	+	+	+	+	0	+	0	+	+	+	+	+	0	+	+		
R2R2	+	0	+	+	0	0	+	+	0	+	0	+	+	0	0	+	0	+	0	0	0	+	0	0	+	+		
rr	0	0	+	0	+	0	0	+	0	+	0	+	0	+	+	+	0	+	+	+	+	0	+	0	+	+		

Figure 10–2. Antigen profile of three-cell screen set.







Antibody identification

Reagent red cells licensed by FDA for this purpose must express the following antigens: D, C, E, c, e, M, N, S, s, P1, Lea, Leb, K, k, Fya, Fyb, Jka, and Jkb.

Homozygous donors with double-dose expression for the following common antigens: D, C, E, c, e, M, N, S, s, Fya, Fyb, Jka, and Jkb.

Antibodies in the Rh, MNS, Duffy, and Kidd systems most commonly demonstrate dosage.

Table 10–2	Optimal Phase of Reactiv	ity for Some Common Alloantibo	odies	
Phase	Immediate Spin (Room Temperature)	37°C Incubation	Antiglobulin Phase	الخون؟ الخون؟
Antibodies	Lea, Leb	Potent cold (IgM) antibodies (especially those causing hemolysis)	Rh antibodies	
	M, N	Some warm antibodies, if high in titer (e.g., D, E, and K)	Kell	
	Lua		Duffy	
	P1		Kidd	
			S,s	
			Lu ^b	
	Table 10–2 Phase Antibodies	Table 10-2Optimal Phase of ReactivePhaseImmediate Spin (Room Temperature)AntibodiesLea, LebM, NLuaLuaP1	Table 10-2 Optimal Phase of Reactivity for Some Common Alloantibol Phase Immediate Spin (Room Temperature) 37°C Incubation Antibodies Lea, Leb Potent cold (IgM) antibodies (especially those causing hemolysis) M, N Some warm antibodies, if high in titer (e.g., D, E, and K) Lua P1	Table 10-2 Optimal Phase of Reactivity for Some Common Alloantibodies Phase Immediate Spin (Room Temperature) 37°C Incubation Antiglobulin Phase Antibodies Leª, Le ^b Potent cold (IgM) antibodies (especially those causing hemolysis) Rh antibodies M, N Some warm antibodies, if high in titer (e.g., D, E, and K) Kell Lu³ Duffy P1 Kidd Lu³ Lu³



Antibody identification



• مركز تحقية																													
Donor	Cell number	D	с	с	Е	e	Cw	к	k	Kpª	Кр⊳	Js ^a	Js ^b	Fy ^a	FуÞ	Jk ^a	Jkb	Le ^a	Le ^b	P ₁	м	N	s	s	Lua	Lu ^b	Xgª		
R1R1	1	+	+	0	0	+	0	0	+	0	+	0	+	+	+	+	0	0	+	+	+	+	+	+	0	+	+		
R1wR1	2	+	+	0	0	+	+	+	+	0	+	0	+	+	0	0	+	0	+	0	+	0	+	+	0	+	+		
RzR1	3	+	+	0	+	+	0	0	+	0	+	0	+	0	+	+	+	0	+	+	0	+	0	+	0	+	+		
R2R2	4	+	0	+	+	0	0	0	+	0	+	0	+	+	0	+	+	0	+	+	+	0	+	0	0	+	+		
r'r	5	0	+	+	0	+	0	0	+	0	+	0	+	0	0	0	+	+	0	+	+	0	+	+	0	+	0		
r"r	6	0	0	+	+	+	0	0	+	0	+	0	+	+	0	0	+	0	0	+	0	+	0	+	0	+	+		
rr	7	0	0	+	0	+	0	+	+	0	+	0	+	+	0	0	+	0	+	+	0	+	0	+	0	+	+		
Rr	8	0	0	+	0	+	0	0	+	0	+	0	+	0	+	+	0	0	+	0	+	0	+	0	0	+	+		
Rr	9	0	0	+	0	+	0	0	+	0	+	0	+	+	0	+	0	0	+	+	+	+	0	+	0	+	0		
R1r	10	+	+	+	0	+	0	0	+	0	+	0	+	+	0	+	+	0	+	+	+	0	0	+	0	+	+		
R0r	11	+	0	+	0	+	0	0	+	0	+	0	+	+	+	0	+	0	+	+	+	0	0	+	0	+	+		
	Patient Cells																												

Figure 10–5. Antibody identification profile sheet: + indicates the antigen is present on the cell, 0 indicates the antigen is not present on the cell.







Limitations of antibody screening



> 26% of antibodies became undetectable over time.

> The screen cannot detect antibodies directed against low-prevalence antigens.

Antibodies showing dosage may not be detected if none of the screen cells have homozygous expression of the target antigen.

Documentation is so important.







Serum and autologous red cells are tested.

Is not the same as or equivalent to a DAT.

Phenotyping autologous Red Cells.

Transfusion in the past 3 month

TABLE 17-1. Some Causes of a Positive DAT Result

Autoantibodies to intrinsic red cell antigens

Hemolytic transfusion reactions

Hemolytic disease of the fetus and newborn

Drug-induced antibodies

Passively acquired alloantibodies (eg, from donor plasma, derivatives, or immunoglobulin)

Nonspecifically adsorbed proteins (eg, hypergammaglobulinemia, high-dose intravenous immune globulin, or modification of red cell membrane by some drugs)

Complement activation due to bacterial infection, autoantibodies, or alloantibodies

Antibodies produced by passenger lymphocytes (eg, in transplanted organs or hematopoietic components)

DAT = direct antiglobulin test



Interpretation of Results



- In what phase(s) did the reaction(s) occur? Cold or warm?
- Is the autologous control negative or positive?
- -No transfusion in past 3 months: autoantibodies or antibodies to medications.
- -Transfusion in past 3 months: alloantibodies coating the circulating donor RBCs.
- Did more than one screen cell sample react? **multiple or high prevalence or auto**?
- Is <u>hemolysis or mixed-field</u> agglutination present?
- Are the cells truly agglutinated, or is rouleaux present?





Interpretation of results

Evaluation of antibody screen results
The autologous control
DAT
Patient history (i.e., age, sex, race, diagnosis)
Pregnancy

- Transfusion history
- Current medications
- Intravenous solutions
- IVIG and RhIG





Selecting blood for transfusion

> Finding antigen negative blood for patient (phenotype match is recommended).

Performing cross match.

Issue blood to hospital.

Follow up patient.



The process of accepting samples from hospitals



16

Send sample with the doctor's request and the results obtained in the blood bank



Testing in *immunohematology* lab and compare the results with blood bank's results. prepare blood for the patient and inform the blood bank of our answer. Sending ag negative blood for subsequent request while crossmatch is compatible.

When Rare Blood Is Needed?

negative for high-prevalence antigens.

negative for a combination of common antigens.







Incompatible blood??

- Autoantibody
- Consultation
 - -Least incompatible for transfusion (with doctor's permission).
- Invivo crossmatch
 - -25-50mlRBC transfusion
 - -Check patient
 - -After 30 min, take sample for serum hemolysis.





When rare blood is needed?

- IBTO



For infants with HDFN resulting from multiple antibodies or an antibody to a high-prevalence antigen, the mother (if she is ABO compatible) is often the logical donor.



Case presentation



20





Case presentation

> 29 years old girl with acute myeloid leukemia.

> After receiving several units of blood, severe hemolysis occurred.

≻ Hb of patient dropped till 3gr/dl.





ABO Discrepancy





23



Case presentation(Cont)

	Anti-A	Anti-B	Anti-A1	A ₁ Cells	A ₂ Cells	B Cells
	4+	0	4+	3+	0	4+
After prewarm	4+	0	NT	0	0	4+





Antibody screening

	Rh			Rh Kell			ell	Dı	ıffy	Kidd		Lev	MNS				Lu	Ith	RT	37	AHG			
	D	С	С	Е	е	κ	k	kр ^ь	Fy	Fy ^b	Jk ^a	Jk ^b	Le ^a	Le ^b	Μ	Ν	S	S	Lu ^a	Lu ^b				
I	+	+	0	0	+	0	+	+	+	+	0	+	+	0	+	0	+	0	0	+	4+	4+	4+	
II	+	0	+	+	0	0	+	+	+	0	+	+	0	+	+	+	0	+	0	+	3+	2+	3+	
III	0	0	+	0	+	+	+	+	0	+	+	0	0	+	0	+	+	+	0	+	2+	2+	2+	
AC																		0	0	2+				



Antibody identification



	Rh					K	əll	Duffy		Kidd		Lev	vis		Μ	NS		Luth		RT	37	AHG
	D	С	С	¥	е	¥	k	Fy ^a	Fy⊳	Jk ^a	Jk ^b ★	Le ^a	Le ^b	M	N	S.	S	Lu ^a	Lu ^b			
1	+	+	0	0	+	0	+	0	+	+	+	0	+	0	+	+	+	0	+	2+	3+	3+
2	+	+	0	0	+	0	+	+	0	+	0	+	0	0	+	0	+	0	+	0	0	0
<u>⁄</u> 3	+	0	+	+	0	0	+	0	+	0	+	+	0	+	+	0	+	0	+	1+	3+	3+
4	+	0	+	+	0	0	+	0	0	+	0	+	0	+	0	+	+	0	+	3+	3+	3+
5	+	+	+	+	+	+	0	0	+	+	0	0	+	+	+	0	+	0	+	2+	3+	4+
6	0	+	+	0	+	0	+	+	+	+	+	0	+	+	0	+	+	0	+	3+	3+	4+
7	0	0	+	0	+	0	+	0	+	+	0	0	+	0	+	0	+	0	+	0	0	0
8	0	0	+	0	+	+	+	+	+	0	+	+	0	0	+	+	0	0	+	1+	2+	3+
9	+	0	+	0	+	0	+	0	0	0	+	0	0	+	+	0	+	+	+	3+	2+	3+
10	0	+	+	+	+	0	+	++	+	+	+	+	+	+	0	+	+	0	+	3+	3+	4+
11	+	+	+	+	+	0	+	+	0	0	0	++	0	+	+	0	0	0	+	3+	3+	3+



26



Case presentation(Cont)

> Positive with all other selected cells.

The patient's RBC phenotype was as follows: D+C+c+E-e+,K-,M-N+S-s+,JK(a+b-),Fy(a+b+).

Antibodies of patient was Anti-E, Anti-M, Anti-S and Anti-JKb.



We can save patients if:



Take antibody screening and Crossmatch serious.

Do the tests accurate and precise.

Send us your complete results.

Contact us as soon as possible.

Close communication between doctors, blood bank staff and immunohematology lab.

You are never wrong to do the right thing !

